Explore the Knowledge Graph

Clinical trials

Trials joined to the biology they test and the companies that run them

Coverage

  • 251,000+ trials from ClinicalTrials.gov, including every trial with a drug intervention registered since 2020.
  • Free text turned into structured fields: normalized sponsors and conditions, structured eligibility, categorized stop reasons, and typed trial arms.
  • 11.6M+ adverse events, normalized and connected onward to MedDRA, UMLS, SNOMED CT, MeSH, and ICD-10.

Where it connects

Trial record NCT03574597 phase 3 · completed
Drugs Each arm's intervention, resolved to a drug record

experimental

titleSemaglutide drugbank_idDB13928

placebo_comparator

titlePlacebo (semaglutide) drugbank_idnull
Targets The mechanism, reached through the intervention drug
nameGlucagon-like peptide 1 receptor biodb_idBE0000857 typeTargetBond agonisttrue pharmacological_actionyes +4 more proteins
Diseases The condition studied, connected to other ontologies
titleObesity drugbank_idDBCOND0015947 icd10c/E66 meddrapt/10029883 mesht/T029022 snomedc/414916001 +1 more condition
Companies The sponsor as filed, and the parent that owns it today
trial_idNCT03574597 sponsors.titleNovo Nordisk A/S companies.nameNovo Nordisk

1,560 trials roll up to this parent, 98 of them through 8 absorbed companies

Zoom in

Stopped trials, by category
identifierstatuswhy_stoppedcategorysafety_efficacy_concern
NCT03263091terminatedStudy did not meet its primary efficacy endpoint.Efficacy1
NCT02412631terminatedLorcaserin removed from marketDrug Recall1
NCT00873002terminatedDose Limiting ToxicityMTD was Reached1
NCT05893069suspendedFDA withdrew approval of the study productDrug Recall1
NCT03147690terminatedStopped for futilityFutility0
NCT02321319terminatedBusiness decision - product discontinuedBusiness Decision0
NCT04080908terminatedUnable to meet enrollment goals.Recruitment0
Eligibility fields, by trial
trial_idgendergender_basedmin_agemax_agehealthy_volunteers
NCT03574597All045 Years[]No
NCT03113773All018 Years85 YearsNo
NCT06724900Female118 Years75 YearsAccepts Healthy Volunteers
NCT04878731Male118 Years74 YearsNo
NCT02851797Male16 Years17 YearsNo
NCT05099484Female118 Years45 Years[]
NCT03036124 outcome measures
outcome_typetitletime_frame
primarySubjects Included in the Composite Endpoint of CV Death, Hospitalization for Heart Failure or Urgent Heart Failure VisitUp to 27.8 months.
secondarySubjects Included in the Composite Endpoint of ≥50% Sustained Decline in eGFRUp to 27.8 months.
secondaryEvents Included in the Composite Endpoint of Recurrent Hospitalization for Heart FailureUp to 27.8 months.
secondaryChange From Baseline in the KCCQ Total Symptom ScoreBaseline and 8 months or death before 8 months
secondarySubjects Included in the Composite Endpoint of CV Death or Hospitalization for Heart FailureUp to 27.8 months.
secondarySubjects Included in the Endpoint of All-cause Mortality.Up to 27.8 months.
NCT03574597 adverse events
arm_group.kindevent_typeevent_termcondition_idnum_affected
experimentalseriousAcute myocardial infarctionDBCOND0032772209
placebo_comparatorseriousAcute myocardial infarctionDBCOND0032772293
experimentalseriousCholelithiasisDBCOND000093744
placebo_comparatorseriousCholelithiasisDBCOND000093731
experimentalotherNauseaDBCOND00106991592
placebo_comparatorotherNauseaDBCOND0010699337
experimentalotherDiarrhoeaDBCOND0126047933
placebo_comparatorotherDiarrhoeaDBCOND0126047353

+3,528 more adverse events on this trial

NCT07241390 sites
facility_namecountryzipstatus
RadboudumcNetherlands6525 GARecruiting
Centro Cardiologico MonzinoItaly20138Recruiting
Futuremeds-NewcastleUnited KingdomNE6 1SGRecruiting
Changzhou Second People's HospitalChina213000Recruiting
Central India Cardiology and Research InstituteIndia440015Recruiting
Medical Center SalutemUkraine21001Recruiting
CEINV SaludMexico64020Not yet recruiting

555 sites across 38 countries on this trial

Questions it answers

  • Who is running trials against a given mechanism, and at what phase? Landscape and whitespace analysis
  • Has this target shown human proof of concept, and on which outcome measures? Target diligence
  • Why did trials in this indication stop, and was safety one of the reasons? Risk assessment

All figures pulled as of November 2026.

Get answers you can trust, every time.